Line BjÃ¸rge

List of Publications by Year
in descending order

135 papers	5,204 citations	109321 35 h-index	106344 65 g-index
147 all docs	147 docs citations	147 times ranked	10077 citing authors

#	Article	IF	Citations
1	Landscape of genomic alterations in cervical carcinomas. Nature, 2014, 506, 371-375.	27.8	708
2	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
3	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
4	Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncology, The, 2016, 17, 78-89.	10.7	205
5	Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncology, The, 2019, 20, 1409-1419.	10.7	179
6	The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nature Genetics, 2016, 48, 848-855.	21.4	174
7	Epigenome-based cancer risk prediction: rationale, opportunities and challenges. Nature Reviews Clinical Oncology, 2018, 15, 292-309.	27.6	129
8	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	1.9	111
9	Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study. Lancet Oncology, The, 2019, 20, 1171-1182.	10.7	108
10	Complement-regulatory proteins in ovarian malignancies. , 1997, 70, 14-25.		106
11	Preoperative tumor texture analysis on MRI predicts high‐risk disease and reduced survival in endometrial cancer. Journal of Magnetic Resonance Imaging, 2018, 48, 1637-1647.	3.4	91
12	Shared heritability and functional enrichment across six solid cancers. Nature Communications, 2019, 10, 431.	12.8	88
13	Validity of the diagnosis of pre‐eclampsia in the Medical Birth Registry of Norway. Acta Obstetricia Et Gynecologica Scandinavica, 2013, 92, 943-950.	2.8	82
14	A transcriptional profile of the decidua in preeclampsia. American Journal of Obstetrics and Gynecology, 2011, 204, 84.e1-84.e27.	1.3	81
15	Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics, 2015, 47, 888-897.	21.4	78
16	Metabolic Tumor Volume on ^{18}F-FDG PET/CT Improves Preoperative Identification of High-Risk Endometrial Carcinoma Patients. Journal of Nuclear Medicine, 2015, 56, 1191-1198.	5.0	78
17	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast‐ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
18	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 2016, 108, djv315.	6.3	77

#	ARTICLE	IF	CITATIONS
19	Placental inflammation in pre-eclampsia by Nod-like receptor protein (NLRP)3 inflammasome activation in trophoblasts. Clinical and Experimental Immunology, 2018, 193, 84-94.	2.6	75
20	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895.	1.9	71
21	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	2.9	68
22	Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunology, Immunotherapy, 2015, 64, 337-347.	4.2	67
23	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	12.8	63
24	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. Cancer Research, 2018, 78, 5419-5430.	0.9	54
25	Oral contraception, body mass index, and asthma: A cross-sectional Nordic-Baltic population survey. Journal of Allergy and Clinical Immunology, 2009, 123, 391-397.	2.9	53
26	Preoperative Tumor Size at MRI Predicts Deep Myometrial Invasion, Lymph Node Metastases, and Patient Outcome in Endometrial Carcinomas. International Journal of Gynecological Cancer, 2015, 25, 459-466.	2.5	53
27	Metabolic profiles of placenta in preeclampsia using HR-MAS MRS metabolomics. Placenta, 2015, 36, 1455-1462.	1.5	53
28	Adverse Pregnancy Outcomes After Treatment for Cervical Intraepithelial Neoplasia. Obstetrics and Gynecology, 2016, 128, 1265-1273.	2.4	50
29	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.9	49
30	Whole-genome microarray and targeted analysis of angiogenesis-regulating gene expression (ENG,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 Maternal-Fetal and Neonatal Medicine, 2008, 21, 267-273.	1.5	48
31	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	2.5	44
32	Medical abortion with mifepristone and home administration of misoprostol up to 63Âdays' gestation. Acta Obstetricia Et Gynecologica Scandinavica, 2014, 93, 647-653.	2.8	43
33	Respiratory health in women: from menarche to menopause. Expert Review of Respiratory Medicine, 2012, 6, 187-202.	2.5	41
34	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Human Molecular Genetics, 2015, 24, 3595-3607.	2.9	40
35	Final results from GCIG/ENGOT/AGOâ€OVAR 12, a randomised placeboâ€controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. International Journal of Cancer, 2020, 146, 439-448.	5.1	40
36	Paroxysmal nocturnal hemoglobinuria in pregnancy. Acta Obstetricia Et Gynecologica Scandinavica, 2003, 82, 1067-1071.	2.8	39

#	Article	IF	Citations
37	Tumour apparent diffusion coefficient is associated with depth of myometrial invasion and is negatively correlated to tumour volume in endometrial carcinomas. Clinical Radiology, 2015, 70, 487-494.	1.1	38
38	Identification of ACOX2 as a shared genetic risk factor for preeclampsia and cardiovascular disease. European Journal of Human Genetics, 2011, 19, 796-800.	2.8	37
39	White Blood Cell <i>BRCA1</i> Promoter Methylation Status and Ovarian Cancer Risk. Annals of Internal Medicine, 2018, 168, 326.	3.9	37
40	Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence. European Radiology, 2013, 23, 2916-2925.	4.5	36
41	Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer. Acta Radiologica, 2018, 59, 1010-1017.	1.1	33
42	High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecologic Oncology, 2020, 157, 260-267.	1.4	32
43	Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. Oncotarget, 2016, 7, 69844-69856.	1.8	30
44	Menstrual Cycle and Respiratory Symptoms in a General Nordicâ€"Baltic Population. American Journal of Respiratory and Critical Care Medicine, 2013, 187, 366-373.	5.6	29
45	Early pregnancy termination with mifepristone and misoprostol in Norway. Acta Obstetricia Et Gynecologica Scandinavica, 2001, 80, 1056-1061.	2.8	28
46	Network-Based Integration of GWAS and Gene Expression Identifies a <i>HOX</i>-Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	2.5	28
47	The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer. PLoS ONE, 2016, 11, e0158208.	2.5	28
48	Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients. British Journal of Cancer, 2017, 117, 840-847.	6.4	26
49	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
50	Common variants at the <i>CHEK2</i> gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	2.8	24
51	Placental inflammation by HMGB1 activation of TLR4 at the syncytium. Placenta, 2018, 72-73, 53-61.	1.5	24
52	CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model. EBioMedicine, 2020, 56, 102783.	6.1	24
53	Soluble CD59 in pregnancy and infancy. Immunology Letters, 1993, 36, 233.	2.5	23
54	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics, 2014, 133, 481-497.	3.8	23

#	ARTICLE	IF	CITATIONS
55	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23
56	Decreased expression of protectin (CD59) in gut epithelium in ulcerative colitis and Crohn's disease*1. Human Pathology, 1999, 30, 1427-1430.	2.0	22
57	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	1.3	22
58	A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway. Acta Obstetricia Et Gynecologica Scandinavica, 2017, 96, 1162-1169.	2.8	22
59	Refined phenotyping identifies links between preeclampsia and related diseases in a Norwegian preeclampsia family cohort. Journal of Hypertension, 2015, 33, 2294-2302.	0.5	21
60	The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples. Nature Communications, 2022, 13, 449.	12.8	21
61	Patient-derived organoids reflect the genetic profile of endometrial tumors and predict patient prognosis. Communications Medicine, 2021, 1, .	4.2	20
62	First In-Mouse Development and Application of a Surgically Relevant Xenograft Model of Ovarian Carcinoma. PLoS ONE, 2014, 9, e89527.	2.5	20
63	The DNA methylome of cervical cells can predict the presence of ovarian cancer. Nature Communications, 2022, 13, 448.	12.8	20
64	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756.	3.8	19
65	Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers. Scientific Reports, 2019, 9, 5244.	3.3	19
66	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18
67	A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. Cancer Chemotherapy and Pharmacology, 2019, 84, 791-798.	2.3	17
68	Consortium analysis of gene and geneâ€"folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition and Food Research, 2014, 58, 2023-2035.	3.3	16
69	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	1.4	15
70	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129.	6.4	15
71	High expression of the p53 isoform Î³ is associated with reduced progression-free survival in uterine serous carcinoma. BMC Cancer, 2018, 18, 684.	2.6	15
72	Cholesterol Crystals and NLRP3 Mediated Inflammation in the Uterine Wall Decidua in Normal and Preeclamptic Pregnancies. Frontiers in Immunology, 2020, 11, 564712.	4.8	15

#	Article	IF	Citations
73	The antihypertensive MTHFR gene polymorphism rs17367504-G is a possible novel protective locus for preeclampsia. Journal of Hypertension, 2017, 35, 132-139.	0.5	15
74	Medical abortion in the first trimester: The use of serum hCG and endometrial thickness as markers of completeness. European Journal of Contraception and Reproductive Health Care, 2007, 12, 366-371.	1.5	14
75	Metabolomics Identifies Placental Dysfunction and Confirms Flt-1 (FMS-Like Tyrosine Kinase Receptor 1) Biomarker Specificity. Hypertension, 2019, 74, 1136-1143.	2.7	14
76	CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma. EBioMedicine, 2020, 56, 102782.	6.1	14
77	TLR3 expression by maternal and fetal cells at the maternal-fetal interface in normal and preeclamptic pregnancies. Journal of Leukocyte Biology, 2021, 109, 173-183.	3.3	14
78	Final survival analysis of NSGO-AVANOVA2/ENGOT-OV24: Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancerâ€"A randomized controlled chemotherapy-free study.. Journal of Clinical Oncology, 2020, 38, 6012-6012.	1.6	14
79	Early pregnancy termination with mifepristone and misoprostol in Norway. Acta Obstetricia Et Gynecologica Scandinavica, 2001, 80, 1056-1061.	2.8	13
80	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget, 2016, 7, 72381-72394.	1.8	13
81	Implementing medical abortion with mifepristone and misoprostol in Norway 1998â€"2013. International Journal of Epidemiology, 2017, 46, dyw270.	1.9	12
82	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12
83	The Emerging Role of CD24 in Cancer Theranosticsâ€"A Novel Target for Fluorescence Image-Guided Surgery in Ovarian Cancer and Beyond. Journal of Personalized Medicine, 2020, 10, 255.	2.5	11
84	Divergent Regulation of Decidual Oxidative-Stress Response by NRF2 and KEAP1 in Preeclampsia with and without Fetal Growth Restriction. International Journal of Molecular Sciences, 2022, 23, 1966.	4.1	11
85	Failed medical termination of twin pregnancy with mifepristone: a case report. Contraception, 2005, 71, 231-233.	1.5	10
86	Decidual and placental NOD1 is associated with inflammation in normal and preeclamptic pregnancies. Placenta, 2021, 105, 23-31.	1.5	10
87	ENGOT-OV24-NSGO/AVANOVA: Niraparib versus bevacizumab-niraparib combination versus bevacizumab and niraparib as sequential therapy in women with platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer.. Journal of Clinical Oncology, 2015, 33, TPS5607-TPS5607.	1.6	10
88	Combination of niraparib and bevacizumab versus niraparib alone as treatment of recurrent platinum-sensitive ovarian cancer: A randomized controlled chemotherapy-free studyâ€"NSGO-AVANOVA2/ENGOT-OV24.. Journal of Clinical Oncology, 2019, 37, 5505-5505.	1.6	10
89	Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models. Cancers, 2020, 12, 370.	3.7	10
90	Changes in Chromatin Structure in Curettage Specimens Identifies High-Risk Patients in Endometrial Cancer. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 61-67.	2.5	9

#	Article	IF	Citations
91	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	2.5	9
92	Asparaginase–like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study. BJOG: an International Journal of Obstetrics and Gynaecology, 2018, 125, 1695-1703.	2.3	9
93	Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. Oncotarget, 2017, 8, 106989-107001.	1.8	9
94	Heterogeneous expression of CD59 on human Purkinje cells. Neuroscience Letters, 2004, 362, 21-25.	2.1	8
95	Pregnancy Outcomes After Paternal Radiofrequency Field Exposure Aboard Fast Patrol Boats. Journal of Occupational and Environmental Medicine, 2012, 54, 431-438.	1.7	8
96	The Norwegian preeclampsia family cohort study: a new resource for investigating genetic aspects and heritability of preeclampsia and related phenotypes. BMC Pregnancy and Childbirth, 2015, 15, 319.	2.4	8
97	Within-subject biological variation of activated partial thromboplastin time, prothrombin time, fibrinogen, factor VIII and von Willebrand factor in pregnant women. Clinical Chemistry and Laboratory Medicine, 2018, 56, 1297-1308.	2.3	8
98	C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease. PLoS ONE, 2017, 12, e0182030.	2.5	8
99	Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock. Genome Biology, 2022, 23, 52.	8.8	8
100	Late-week surgical treatment of endometrial cancer is associated with worse long-term outcome: Results from a prospective, multicenter study. PLoS ONE, 2017, 12, e0182223.	2.5	7
101	In Âvivo MR spectroscopy predicts high tumor grade in endometrial cancer. Acta Radiologica, 2018, 59, 497-505.	1.1	7
102	A phase I study of bevacizumab in combination with niraparib in patients with platinum-sensitive epithelial ovarian cancer: The ENGOT-OV24/AVANOVA1 trial.. Journal of Clinical Oncology, 2016, 34, 5555-5555.	1.6	7
103	Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. Oncotarget, 2017, 8, 64670-64684.	1.8	7
104	Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. Oncotarget, 2017, 8, 68530-68541.	1.8	7
105	Comparison of Five Near-Infrared Fluorescent Folate Conjugates in an Ovarian Cancer Model. Molecular Imaging and Biology, 2023, 25, 144-155.	2.6	7
106	A national precision cancer medicine implementation initiative for Norway. Nature Medicine, 2022, 28, 885-887.	30.7	7
107	Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway. Journal of Translational Medicine, 2022, 20, 225.	4.4	7
108	No effects of MRI scan on male reproduction hormones. Reproductive Toxicology, 2012, 34, 133-139.	2.9	6

#	Article	IF	Citations
109	A phase 1 study to evaluate the safety and tolerability of bevacizumab-niraparib combination therapy and determine the recommended phase 2 dose (RP2D) in women with platinum-sensitive epithelial ovarian cancer (ENGOT-OV24/AVANOVA1). Annals of Oncology, 2017, 28, v339.	1.2	6
110	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. Cancer Medicine, 2019, 8, 2503-2513.	2.8	6
111	Establishment of a novel cancer cell line derived from vulvar carcinoma associated with lichen sclerosus exhibiting a fibroblast-dependent tumorigenic potential. Experimental Cell Research, 2020, 386, 111684.	2.6	6
112	Phenotypic Characterization by Mass Cytometry of the Microenvironment in Ovarian Cancer and Impact of Tumor Dissociation Methods. Cancers, 2021, 13, 755.	3.7	6
113	Identification of a Locus Near <i>ULK1</i> Associated With Progression-Free Survival in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 1669-1680.	2.5	5
114	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	1.8	5
115	Fluorochrome Selection for Imaging Intraoperative Ovarian Cancer Probes. Pharmaceuticals, 2022, 15, 668.	3.8	5
116	Humanized Ovarian Cancer Patient-Derived Xenografts for Improved Preclinical Evaluation of Immunotherapies. Cancers, 2022, 14, 3092.	3.7	5
117	Concentration of fibrin monomer in pregnancy and during the postpartum period. Annals of Clinical Biochemistry, 2019, 56, 692-700.	1.6	4
118	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 420-424.	2.5	3
119	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	4.1	3
120	DNA methylation signatures to predict the cervicovaginal microbiome status. Clinical Epigenetics, 2020, 12, 180.	4.1	3
121	CA-125 Levels Are Predictive of Survival in Low-Grade Serous Ovarian Cancerâ€"A Multicenter Analysis. Cancers, 2022, 14, 1954.	3.7	3
122	Xenograft Models of Ovarian Cancer for Therapy Evaluation. Methods in Molecular Biology, 2022, 2424, 275-293.	0.9	2
123	Prototype precision oncology learning ecosystem: Norwegian precision cancer medicine implementation initiative.. Journal of Clinical Oncology, 2022, 40, e13634-e13634.	1.6	2
124	NLRP3 inflammasome expression by maternal and fetal cells in the decidua and its association with preeclampsia. Placenta, 2019, 83, e15.	1.5	1
125	Real-life data of niraparib maintenance treatment in patients with recurrent platinum-sensitive ovarian cancer.. Journal of Clinical Oncology, 2021, 39, 5560-5560.	1.6	1
126	[278-POS]. Pregnancy Hypertension, 2015, 5, 138-139.	1.4	0

#	Article	IF	Citations
127	NLRP3 inflammasome expression and activation at the maternal-fetal interface in preeclamptic and healthy pregnancies. Placenta, 2016, 45, 88.	1.5	0
128	Metabolomics identifies placental dysfunction and confirms Flt-1 biomarker specificity. Pregnancy Hypertension, 2019, 17, S5.	1.4	0
129	Abstract 4604: Landscape of human and viral genomic alterations in cervical carcinomas.. , 2013, , .		0
130	Abstract 4692: Relationships between somatic genomic alterations, tumor stage and progression-free survival in cervical cancer. , 2014, , .		0
131	Palbociclib versus placebo in combination with letrozole for patients with advanced or recurrent endometrial cancer: The NSGO ENGOT-EN3/PALEO trial.. Journal of Clinical Oncology, 2017, 35, TPS5612-TPS5612.	1.6	0
132	Toll-like receptor 3 expression and activation at the maternal-fetal interface in pregnancy. Clinical Medicine, 2019, 19, s104-s104.	1.9	0
133	Abstract A16: Patient-derived organoid-based models for endometrial cancer. , 2020, , .		0
134	Kreftoppfølgingen bør endres. Tidsskrift for Den Norske Laegeforening, 2020, 140, .	0.2	0
135	Symptomatic or asymptomatic recurrence of ovarian cancer: does it influence survival?. International Journal of Gynecological Cancer, 0, , ijgc-2022-003361.	2.5	0